Changing the Course of Cancer Treatment
AdvanCell is a clinical stage radiopharmaceutical company developing treatments to significantly improve survival and quality of life for patients with cancer.
.webp)
Play Video
829665046
Development Pipeline
AdvanCell is delivering a portfolio of therapies to market for the treatment of prostate cancer, melanoma, pancreatic cancer, breast cancer and colorectal cancer.
Groundbreaking Technology
THERAPIES
Proprietary ²¹²Pb production technology provides access to an unmatched supply of alpha isotopes to accelerate clinical development of a portfolio of targeted alpha therapies.
Read more
.webp)
ALPHA 212 SUPPLY
Alpha 212 is the product of AdvanCell’s ²¹²Pb generator. It is a quality-controlled dose of ²¹²Pb as an Active Pharmaceutical Ingredient (API) manufactured to international GMP standards.
Read more
.svg)
